- Home
- IFBD vs BCAB Comparison
IFBD vs BCAB Comparison
Compare IFBD & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IFBD | BCAB |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 7.4M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IFBD | BCAB |
|---|---|---|
| Price | $1.03 | $6.14 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.2K | ★ 482.5K |
| Earning Date | 05-01-2023 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.12 |
| 52 Week High | $1.69 | $6.52 |
Technical Indicators
Market Signals| Indicator | IFBD | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 80.30 |
| Support Level | $1.01 | $0.36 |
| Resistance Level | $1.08 | $6.52 |
| Average True Range (ATR) | 0.07 | 0.56 |
| MACD | 0.01 | 0.23 |
| Stochastic Oscillator | 54.29 | 91.87 |
Price Performance
Historical ComparisonAbout IFBD Infobird Co. Ltd
Infobird Co Ltd is engaged in developing and providing customer engagement cloud-based services. It software-as-a-service provider of AI-powered, or artificial intelligence-enabled, customer engagement solutions in China. It provides holistic software solutions to help corporate clients proactively deliver and manage end-to-end customer engagement activities at all stages of the sales process, including pre-sales and sales activities, and post-sales customer support. It also offers AI-powered cloud-based sales force management software, including intelligent quality inspection and intelligent training software to help clients monitor, benchmark, and improve the performance of agents.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.